ESR1 and breast carcinoma: In a randomised, double-blind study in PMW (N=337) with ER+ and/or PgR+ breast cancer comparing letrozole with tamoxifen (Eiermann et al, 2001), letrozole was superior to tamoxifen in overall objective response rate (55 vs 36% P<0.001).